Generic pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Monday that it recorded a net loss of USD7.6m (USD0.20 per share) for its fiscal fourth quarter ended 30 June 2019.
This is an improvement in earnings when compared with a higher net loss of USD11.4m (USD0.30 per share) for the fiscal 2018 fourth quarter.
GAAP net sales of USD133.8m were recorded for its fiscal fourth quarter ended 30 June 2019, down over USD170.9m for the fourth quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.4m were reported for its fiscal fourth quarter ended 30 June 2019, a rise versus R&D of USD8.3m for the fiscal 2018 fourth quarter.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream